Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord mesenchymal stem cells (Beike Biotechnology)
- Development stage
- Unknown
- Lead developer
- Beike Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Topical
01
Overview
This cell therapy product consists of allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) derived from Wharton's jelly. It is being investigated by Jie Shen in collaboration with Shenzhen Beike Biotechnology for the treatment of diabetic foot ulcers (DFU) and peripheral arterial disease (PAD). The therapy functions through paracrine signaling, secreting pro-angiogenic factors like vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), which promote revascularization and tissue repair. Additionally, these cells exhibit immunomodulatory and anti-inflammatory properties, helping to resolve the chronic inflammatory state associated with non-healing diabetic wounds. In clinical studies, the cells have been administered via both intravenous infusion and topical application to the ulcer site.
- Other names
- human umbilical cord mesenchymal stem cellshUC-MSCs
Beyond the preview
Go deeper on umbilical cord mesenchymal stem cells (Beike Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (Beike Biotechnology).